Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sun Pharma Completes Acquisition of Concert Pharmaceuticals (3/06/23)
- Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma's Global Dermatology Portfolio
MUMBAI, India and PRINCETON, N.J., March 6, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata.
"We are excited to add deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to our growing global dermatology portfolio and expand our presence in the Boston biotech hub," said Abhay Gandhi, CEO North America, Sun Pharma. "By bringing together Concert's talented team with Sun Pharma's global reach and commercial capabilities, this acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patients around the world."
Sun Pharma's tender offer to acquire all outstanding shares of Concert's common stock for (i) $8.00 per share in cash, subject to any applicable withholding of taxes and without interest (the "Common Cash Amount"), plus (ii) one non-transferable contingent value right (each, a "CVR") per share (the "Common CVR Amount" and together with the Common Cash Amount, the "Offer Price"), subject to any applicable withholding of taxes and without interest, which represents the contractual right to receive contingent payments of up to $3.50 per share, in cash, in the aggregate, subject to any applicable withholding of taxes and without interest, upon the achievement of certain milestones described below prior to December 31, 2029, expired one minute after 11:59 p.m. New York City time on Friday, March 3, 2023. The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 48,220,511 shares of Concert's common stock were validly tendered and not withdrawn in the tender offer, which represent approximately 75.2% of the total number of shares of Concert's outstanding common stock.
Following the acceptance of the tendered shares, Sun Pharma completed the acquisition of Concert through the merger of a wholly owned subsidiary of Sun Pharma with and into Concert in which (i) each share of Concert's common stock not tendered into the offer (other than shares (a) held in Concert's treasury, (b) owned by Sun Pharma, any subsidiary of Sun Pharma or any subsidiary of Concert or (c) shares held by Concert stockholders who properly demanded appraisal for their shares under Delaware law) was converted into the right to receive the Offer Price and (ii) each share of Concert's Series X1 Preferred Stock (other than shares (a) held in Concert's treasury or (b) shares held by Concert stockholders who properly demanded appraisal for their shares under Delaware law) was converted into the right to receive (1) the Common Cash Amount multiplied by 1,000, in cash, subject to any applicable withholding of taxes and without interest, plus (2) the Common CVR Amount multiplied by 1,000, subject to any applicable withholding of taxes and without interest, which represents the right to receive contingent payments of up to $3.50 per CVR, in cash, in the aggregate, subject to any applicable withholding of taxes and without interest, upon the achievement of certain milestones prior to December 31, 2029. As a result of the merger, Concert became a wholly owned subsidiary of Sun Pharma. The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market.
For additional background on the acquisition, please read the announcement press release here.
About Deuruxolitinib and Alopecia Areata
Deuruxolitinib is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration recently maintained Breakthrough Therapy designation for deuruxolitinib for the treatment of adult patients with moderate to severe alopecia areata and previously granted Fast Track designation for deuruxolitinib for the treatment of alopecia areata.
Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 2.5% of the United States and global population during their lifetime.1,2,3 The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently limited treatment options available for alopecia areata.
Disclaimer:
Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.
References:
Benigno M. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States, Clinical, Cosmetic and Investigational Dermatology 2020.
Lee HH et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis, J Am Acad Dermatol. 2020 Mar; 82(3):675-682.
Fricke et al. Epidemiology and burden of alopecia areata: a systematic review, Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403.)
About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)
Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com and follow us on Twitter @SunPharma_Live.
https://www.prnewswire.com/news-releases/sun-pharma-completes-acquisition-of-concert-pharmaceuticals-301763327.html
Wish it would get back to 28
Took a year to get back to today price range a break of this range
Will take us to double digits
Price targets.
It’s like clockwork
Always on time!!!
Looks like we won our patent case! Now we just need pos p3 data and were off!
There has to be some reason why they are paying more than market price for offering. I believe this will go up from here. It bottomed out. There will be follow-up news once offering is closed. Also, they is no risk of dilution until end of 2022 since they will have enough money to conduct trial.
Hello $CNCE
I like what I see here
Looks like we ready!!!!
Grateful for the opportunity !!!!
Let’s go $CNCE—————>
$CNCE recent news/filings
bullish
## source: finance.yahoo.com
Wed, 27 May 2015 11:29:06 GMT ~ Concert Pharmaceuticals to Present at Two Upcoming Investor Conferences
[at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Jefferies ...
read full: http://www.noodls.com/view/D231E016A766700686ED07DBBBF100FBE0715CFA
*********************************************************
Wed, 27 May 2015 11:00:00 GMT ~ Concert Pharmaceuticals to Present at Two Upcoming Investor Conferences
[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences:
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-present-two-upcoming-110000567.html
*********************************************************
Tue, 19 May 2015 17:04:19 GMT ~ CONCERT PHARMACEUTICALS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=cnce
*********************************************************
Tue, 12 May 2015 11:12:17 GMT ~ Concert Pharmaceuticals to Present at the UBS Global Healthcare Conference
[at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the UBS Global Healthcare Conference onTuesday, May 19, 2015 ...
read full: http://www.noodls.com/view/30C3FCF74EC30E6DF22D872C636C50B9F2C672D3
*********************************************************
Tue, 12 May 2015 11:00:00 GMT ~ Concert Pharmaceuticals to Present at the UBS Global Healthcare Conference
[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the UBS Global Healthcare Conference on Tuesday, May 19, 2015 at 11:30 a.m.
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-present-ubs-global-110000268.html
*********************************************************
$CNCE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CNCE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CNCE/company-info
Ticker: $CNCE
OTC Market Place: Not Available
CIK code: not found
Company name: Concert Pharmaceuticals, Inc.
Incorporated In:
$CNCE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$CNCE extra dd links
Company name: Concert Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CNCE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CNCE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CNCE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/news - http://finance.yahoo.com/q/h?s=CNCE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CNCE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CNCE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CNCE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Concert+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Concert+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Concert+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CNCE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CNCE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CNCE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CNCE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CNCE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CNCE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CNCE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CNCE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CNCE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CNCE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CNCE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CNCE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CNCE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CNCE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CNCE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CNCE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNCE
$CNCE DD Notes ~ http://www.ddnotesmaker.com/CNCE
Sounds cool. I just loaded last week. You are not playing CLDN?
Only stock I am buying right now. Time will make this one huge and only thing holding it back is fear of conception. It has been proved and needs a good article or news to make it really really BIG.
Mean time, I am hoping for a failure on the JAZZ trial. That would drive it down a few bucks and allow much more loading...
Double in 4 weeks?
$CNCE NEWS: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
A patent issued... Still holding out hopes that AVNR does not sell out.
bing... Nice empty board... Stay away !!!!!!!
$CNCE DD Notes ~ http://www.ddnotesmaker.com/CNCE
bullish
double bottom W pattern
$CNCE recent news/filings
## source: finance.yahoo.com
Wed, 15 Oct 2014 21:04:59 GMT ~ Concert Pharmaceuticals Announces Positive CTP-354 Data
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-announces-positive-ctp-210459839.html
*********************************************************
Mon, 13 Oct 2014 11:00:00 GMT ~ Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity
[Business Wire] - Concert Pharmaceuticals, Inc. announced today Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-presents-positive-data-110000779.html
*********************************************************
Mon, 29 Sep 2014 16:07:00 GMT ~ Five Reasons Celgene Could Gain 20%
read full: http://blogs.barrons.com/stockstowatchtoday/2014/09/29/five-reasons-celgene-could-gain-20/?mod=yahoobarrons&ru=yahoo
*********************************************************
Wed, 17 Sep 2014 11:00:00 GMT ~ Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration
[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation.
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-announces-initiation-ctp-110000464.html
*********************************************************
Tue, 16 Sep 2014 11:02:52 GMT ~ Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8%
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-cnce-soars-stock-110252735.html
*********************************************************
$CNCE charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$CNCE company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CNCE/company-info
Ticker: $CNCE
OTC Market Place: Not Available
CIK code: not found
Company name: Concert Pharmaceuticals, Inc.
Incorporated In:
$CNCE share structure
## source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$CNCE extra dd links
Company name: Concert Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CNCE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CNCE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CNCE+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/news - http://finance.yahoo.com/q/h?s=CNCE+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CNCE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CNCE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CNCE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Concert+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Concert+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Concert+Pharmaceuticals%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CNCE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CNCE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CNCE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CNCE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CNCE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CNCE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CNCE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CNCE+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CNCE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CNCE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CNCE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CNCE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CNCE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CNCE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CNCE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CNCE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNCE
$CNCE DD Notes ~ http://www.ddnotesmaker.com/CNCE
No one even knows about the 923 data on value to Concert. They have big value coming in already on what avinir is selling now AVP -786. The other will be an ADD ON.
That is a PR that is yet to be determined. Not sure as to what the royalities are, I have read that it covers their burn rate at the very least.
If JAZZ uses it, sky is the limit.
It is time to sit on the sidelines and just hold for a while. No volome what so ever and the reason,..... no one will sell...
I am impressed this has held up.
I think it is 4, just submit they will let you know if something is missing.
Or is it 3 posts.
Think you need 2 posts within 24 hours to become a MOD.
I am going to rework this page so everyone understands what the DCE platform is and how it works. It is making Avinir a name in meds, going to help JAA and Celegene too.
More... More again... Me... and Me too...
Get it cheaper, just wait a week or 2.. Nothing happening between then and now.
$CNCE $CELG Roth Capital Reiterates Buy On Concert Following Initiation Of Phase I Study http://www.smarteranalyst.com/2014/09/18/roth-capital-reiterates-buy-concert-following-initiation-phase-study/
I am loading up for a lifetime on the next BIG pullback. If fact, wish they had some type of failure. Their founder is brilliant and brought what he knew with him. Their compound are the wave of future medicine.. I hope...
So many medicines fail on poor metabolic stability resulting in failed phase trial testing. Would bet that is why AVINIR was able to bring forth something no one ever thought of...
This leaves Concert in the drivers seat for so so many things. Baker Bros knew to buy them early and you can bet the will go in and get a huge offering at some point...
They are making money, although not enough... The AVP-786 is only the begining for these guys...
I was scepticle until this last trial by AVNR... Now we know... Imagine making a pain reliever that last 3 times longer... What is that worth...OMG !
Everybody was late off of the news... Considering what they do they are a great play, at this price I wouldn't touch it. THey have a way's to go to make any money. As they grow, they can increase their value and stance...
What is the symbol CNCE
Concert Pharmaceuticals, Inc. [$CNCE] due diligence
bullish
$CNCE
DD Notes ~ http://www.ddnotesmaker.com/CNCE
##### recent news/filings ~ source: finance.yahoo.com
Thu, 26 Jun 2014 18:06:38 GMT ~ BUZZ-U.S. Stocks on the Move-Royale Energy, Methode, Concert Pharma
read full: http://uk.finance.yahoo.com/news/buzz-u-stocks-move-royale-180638948.html
*********************************************************
Mon, 16 Jun 2014 20:37:12 GMT ~ CONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
read full: http://biz.yahoo.com/e/140616/cnce8-k.html
*********************************************************
Tue, 27 May 2014 11:00:00 GMT ~ Concert Pharmaceuticals to Present at Upcoming Investor Conferences
[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it will present at the following upcoming conferences:
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-present-upcoming-investor-110000248.html
*********************************************************
Tue, 20 May 2014 17:04:25 GMT ~ CONCERT PHARMACEUTICALS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=cnce
*********************************************************
Wed, 14 May 2014 11:16:56 GMT ~ CONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
read full: http://biz.yahoo.com/e/140514/cnce8-k.html
*********************************************************
##### chart ~ source: stockcharts.com
##### chart ~ source: eoddata.com
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/CNCE/company-info
Ticker: $CNCE
OTC Market Place: Not Available
CIK code: not found
Company name: Concert Pharmaceuticals, Inc.
Incorporated In:
##### extra dd links
Latest filings: http://www.otcmarkets.com/stock/CNCE/filings
Latest financials: http://www.otcmarkets.com/stock/CNCE/financials
Latest news: http://www.otcmarkets.com/stock/CNCE/news - http://finance.yahoo.com/q/h?s=CNCE+Headlines
Major holdings: http://data.cnbc.com/quotes/CNCE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=CNCE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/CNCE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=CNCE
RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=CNCE&search=search
DTCC: http://search2.dtcc.com/?q=Concert+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Concert+Pharmaceuticals%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Concert+Pharmaceuticals%2C+Inc.&x=0&y=0
Short Sales: http://www.otcmarkets.com/stock/CNCE/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/CNCE/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/CNCE/research
Historical Prices: http://finance.yahoo.com/q/hp?s=CNCE+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=CNCE+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=CNCE+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=CNCE+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=CNCE+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=CNCE+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=CNCE
Balance Sheet: http://finance.yahoo.com/q/bs?s=CNCE
Cash Flow: http://finance.yahoo.com/q/cf?s=CNCE+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/CNCE
Bloomberg: http://www.bloomberg.com/quote/CNCE:US
Morningstar: http://quotes.morningstar.com/stock/s?t=CNCE
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNCE
Barchart: http://www.barchart.com/quotes/stocks/CNCE
OTC Short Report: http://otcshortreport.com/index.php?index=CNCE
Investopedia: http://www.investopedia.com/markets/stocks/CNCE/?wa=0
http://www.pennystocktweets.com/stocks/profile/CNCE
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/CNCE
cube1
Followers
|
6
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
41
|
Created
|
06/28/14
|
Type
|
Free
|
Moderators |
Concert Pharmaceuticals, Inc.
Below is a great description of what Concert is all about. The robust pipeline link works and takes you directly to their pipeline chart. The management is top of the line, only worry would be a quick buyout. The board is loaded with flippers that love to sell off what they have started in the past....
They have collaborations with Avinir Pharma, Jazz Pharma, and Celegene Pharma. Have been a public company for only 6 months. Have Revenue already and Avinir just announced that a phase II trial in agitation via ALZ patient had great readings.
Introduction: Building Better Medicines
We are a clinical stage biopharmaceutical company applying its extensive knowledge of deuterium chemistry to discover and develop novel small molecule drugs. Our approach starts with approved drugs, advanced clinical candidates or previously studied compounds that we believe can be improved with deuterium substitution to provide better pharmacokinetic or metabolic properties and thereby enhance clinical safety, tolerability or efficacy. We have executed on this approach to become a clinical stage biotechnology company and are developing a robust pipeline of product candidates in several therapeutic areas.
We apply our DCE Platform to systematically identify approved drugs, advanced clinical candidates or
previously studied compounds that we believe can be improved with deuterium substitution. Potential
advantages of our selective deuteration include:
DCE Platform® - More Efficient and Less Expensive
Unlike traditional methods of drug discovery which involve lengthy processes with high failure rates, our approach generally begins with approved drugs, advanced clinical compounds or previously studied compounds. We prioritize candidate compounds based on medical need, commercial opportunity, competitive and patent landscapes and internal strategic fit. We believe our approach may enable drug discovery and clinical development that is more efficient and less expensive than conventional small molecule drug research and development.
A Novel Drug Discovery Paradigm
The average adult human body contains approximately two grams of deuterium. While essentially
identical to hydrogen in size and shape, deuterium differs from hydrogen in that it contains an additional
neutron. As a result, deuterium forms a more stable chemical bond with carbon than does hydrogen. The
deuterium-carbon bond is typically six to nine times more stable than the hydrogen-carbon bond. This
has important implications for drug development because drug metabolism often involves the breaking of
hydrogen-carbon bonds.
Because deuterium forms more stable bonds with carbon, deuterium substitution can in some cases alter
drug metabolism, including through improved metabolic stability, reduced formation of toxic
metabolites, increased formation of desired active metabolites, or a combination of these effects. At the
same time, because deuterium closely resembles hydrogen, the substitution of deuterium for hydrogen
has generally been found not to materially alter the intrinsic biological activity of a compound.
Deuterated compounds can generally be expected to retain biochemical potency and selectivity similar to
their hydrogen analogs. The effects, if any, of deuterium substitution on metabolic properties are highly
dependent on the specific molecular positions at which deuterium is substituted for hydrogen. In
addition, the metabolic effects of deuterium substitution, if any, are unpredictable, even in compounds
that have similar chemical structures.
A clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, renal disease, inflammation, and cancer. The company’s clinical-stage product candidates include CTP-354, which in Phase I clinical trial for spasticity associated with multiple sclerosis and spinal cord injury; CTP-499 that is in Phase II clinical trial for diabetic kidney disease; and AVP-786 for neurologic and psychiatric disorders. Its preclinical compounds comprise CTP-730 for inflammatory diseases; JZP-386, a deuterated analog of sodium oxybate for narcolepsy; and C-10068, an oral deuterium-substituted analog of dextroethorphan, which is used for the treatment of pain and seizure-generating diseases and injuries, such as epilepsy, ischemic stroke, and traumatic brain injury. The company has collaborations with Avanir Pharmaceuticals, Inc., Celgene Corporation, Celgene International Sàrl, and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.(yahoo)
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |